Amylyx Pharmaceuticals, Inc. (AMLX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Amylyx is a clinical-stage pharmaceutical company focused on developing novel therapies for endocrine conditions and neurodegenerative diseases. The company's primary pipeline includes avexitide for post-bariatric hypoglycemia (PBH), AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis (ALS), and AMX0318 for PBH and other rare diseases. The company is currently operating without product revenue following the voluntary withdrawal of RELYVRIO/ALBRIOZA in 2024.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(41.3) million | $(35.9) million |
| Net Loss Per Share | $(0.37) | $(0.42) |
| Operating Expenses | $43.8 million | $37.8 million |
| Cash, Cash Equivalents & Marketable Securities | $279.8 million | $61.2 million (end of period) |
| Accumulated Deficit | $(792.7) million | $(642.6) million |
| Net Cash Used in Operating Activities | $(36.9) million | $(39.8) million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 16% to $43.8 million, driven by a 25% increase in Research and Development (R&D) expenses to $27.6 million.
- R&D Drivers: The increase in R&D was primarily due to $4.6 million in additional costs for the pivotal Phase 3 LUCIDITY trial for avexitide and a $4.0 million milestone payment to Gubra A/S for the selection of AMX0318 as a development candidate. These increases were partially offset by a $3.9 million decrease in expenses for AMX0035 following the discontinuation of its PSP program.
- Liquidity Position: Cash and marketable securities increased significantly from $61.2 million at the end of Q1 2025 to $279.8 million at the end of Q1 2026, largely due to a $65.6 million equity offering in January 2025 and strong investment income ($2.6 million in Q1 2026).
- Legal Settlement: The company reached an agreement in principle to settle a securities class action lawsuit (Shih Complaint) for $6.5 million, a significant portion of which is expected to be covered by insurance. This liability was not recorded as of March 31, 2026, but is expected to be recognized in Q2 2026.
Guidance, Outlook, and Risks
- Clinical Milestones: Enrollment for the Phase 3 LUCIDITY trial for avexitide in PBH was completed in March 2026. Topline data is expected in Q3 2026, with a potential commercial launch in 2027 if approved. The Phase 1 LUMINA trial for AMX0114 in ALS completed enrollment of Cohort 2 in March 2026.
- Capital Runway: Management believes existing cash, cash equivalents, and marketable securities ($279.8 million) are sufficient to fund operations into 2028.
- Key Risks:
- Regulatory Approval: Success depends heavily on the LUCIDITY trial results and subsequent FDA approval for avexitide.
- Litigation: Pending derivative lawsuits and the finalization of the $6.5 million class action settlement.
- Manufacturing: Reliance on third-party manufacturers for clinical and commercial supply, with potential risks related to supply chain disruptions and capacity constraints for peptide-based therapeutics.
- Capital Needs: While runway extends to 2028, the company may require additional funding sooner if development timelines extend or costs increase.
Investor Verification Checklist
- Verify the final court approval and insurance coverage details for the $6.5 million class action settlement.
- Monitor the Q3 2026 announcement of topline data for the avexitide LUCIDITY Phase 3 trial.
- Review the impact of the $4.0 million Gubra milestone payment on future cash burn rates.
- Assess the status of the derivative lawsuits (Jones, Hassine, and Schweitzer complaints) and potential financial exposure.
- Confirm the timeline for the Expanded Access Program (EAP) for avexitide initiated in May 2026.